JP2011513492A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011513492A5 JP2011513492A5 JP2010550813A JP2010550813A JP2011513492A5 JP 2011513492 A5 JP2011513492 A5 JP 2011513492A5 JP 2010550813 A JP2010550813 A JP 2010550813A JP 2010550813 A JP2010550813 A JP 2010550813A JP 2011513492 A5 JP2011513492 A5 JP 2011513492A5
- Authority
- JP
- Japan
- Prior art keywords
- suspension composition
- volume
- weight
- composition
- drug
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims description 82
- 239000000725 suspension Substances 0.000 claims description 59
- 229940079593 drug Drugs 0.000 claims description 20
- 239000003814 drug Substances 0.000 claims description 20
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims description 16
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 16
- 229920000053 polysorbate 80 Polymers 0.000 claims description 16
- 229940068968 polysorbate 80 Drugs 0.000 claims description 16
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 13
- 239000000375 suspending agent Substances 0.000 claims description 13
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 12
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims description 12
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 10
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 claims description 8
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 claims description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 8
- 230000002776 aggregation Effects 0.000 claims description 8
- 238000004220 aggregation Methods 0.000 claims description 8
- 239000007900 aqueous suspension Substances 0.000 claims description 8
- 239000000872 buffer Substances 0.000 claims description 7
- 239000003795 chemical substances by application Substances 0.000 claims description 7
- 150000003841 chloride salts Chemical class 0.000 claims description 7
- 239000003002 pH adjusting agent Substances 0.000 claims description 7
- 239000008215 water for injection Substances 0.000 claims description 7
- 238000002347 injection Methods 0.000 claims description 6
- 239000007924 injection Substances 0.000 claims description 6
- 229960002117 triamcinolone acetonide Drugs 0.000 claims description 5
- YNDXUCZADRHECN-JNQJZLCISA-N triamcinolone acetonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O YNDXUCZADRHECN-JNQJZLCISA-N 0.000 claims description 5
- MDYZKJNTKZIUSK-UHFFFAOYSA-N tyloxapol Chemical compound O=C.C1CO1.CC(C)(C)CC(C)(C)C1=CC=C(O)C=C1 MDYZKJNTKZIUSK-UHFFFAOYSA-N 0.000 claims description 5
- 229960004224 tyloxapol Drugs 0.000 claims description 5
- 229920001664 tyloxapol Polymers 0.000 claims description 5
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims description 4
- 239000001110 calcium chloride Substances 0.000 claims description 4
- 229910001628 calcium chloride Inorganic materials 0.000 claims description 4
- 229910001629 magnesium chloride Inorganic materials 0.000 claims description 4
- 239000001103 potassium chloride Substances 0.000 claims description 4
- 235000011164 potassium chloride Nutrition 0.000 claims description 4
- 239000003755 preservative agent Substances 0.000 claims description 4
- 230000002335 preservative effect Effects 0.000 claims description 4
- 239000011780 sodium chloride Substances 0.000 claims description 4
- 206010003694 Atrophy Diseases 0.000 claims description 2
- 208000001344 Macular Edema Diseases 0.000 claims description 2
- 206010025415 Macular oedema Diseases 0.000 claims description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 claims description 2
- 208000000208 Wet Macular Degeneration Diseases 0.000 claims description 2
- 230000037444 atrophy Effects 0.000 claims description 2
- 239000006172 buffering agent Substances 0.000 claims description 2
- 208000011325 dry age related macular degeneration Diseases 0.000 claims description 2
- 201000010230 macular retinal edema Diseases 0.000 claims description 2
- 230000035699 permeability Effects 0.000 claims description 2
- 208000004644 retinal vein occlusion Diseases 0.000 claims description 2
- 239000001632 sodium acetate Substances 0.000 claims description 2
- 235000017281 sodium acetate Nutrition 0.000 claims description 2
- 239000001509 sodium citrate Substances 0.000 claims description 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims description 2
- 239000000243 solution Substances 0.000 claims description 2
- CEIJFEGBUDEYSX-FZDBZEDMSA-N tandospirone Chemical compound O=C([C@@H]1[C@H]2CC[C@H](C2)[C@@H]1C1=O)N1CCCCN(CC1)CCN1C1=NC=CC=N1 CEIJFEGBUDEYSX-FZDBZEDMSA-N 0.000 claims description 2
- 229950000505 tandospirone Drugs 0.000 claims description 2
- 208000022873 Ocular disease Diseases 0.000 claims 1
- 230000002708 enhancing effect Effects 0.000 claims 1
- 238000012800 visualization Methods 0.000 claims 1
- 210000004127 vitreous body Anatomy 0.000 claims 1
- 238000000034 method Methods 0.000 description 3
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 208000030533 eye disease Diseases 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US3545908P | 2008-03-11 | 2008-03-11 | |
| US61/035,459 | 2008-03-11 | ||
| PCT/US2009/036652 WO2009114521A1 (en) | 2008-03-11 | 2009-03-10 | Low viscosity, highly flocculated triamcinolone acetonide suspensions for intravitreal injection |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011513492A JP2011513492A (ja) | 2011-04-28 |
| JP2011513492A5 true JP2011513492A5 (https=) | 2012-03-22 |
| JP5581227B2 JP5581227B2 (ja) | 2014-08-27 |
Family
ID=40548758
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010550813A Active JP5581227B2 (ja) | 2008-03-11 | 2009-03-10 | 硝子体内注射のための低粘度、高凝集トリアムシノロンアセトニド懸濁剤 |
Country Status (21)
| Country | Link |
|---|---|
| US (3) | US8128960B2 (https=) |
| EP (1) | EP2262506B1 (https=) |
| JP (1) | JP5581227B2 (https=) |
| KR (1) | KR101555293B1 (https=) |
| CN (1) | CN101959519B (https=) |
| AR (1) | AR070824A1 (https=) |
| AU (1) | AU2009223649B2 (https=) |
| BR (1) | BRPI0909630B8 (https=) |
| CA (1) | CA2717605C (https=) |
| CL (1) | CL2009000573A1 (https=) |
| DK (1) | DK2262506T3 (https=) |
| ES (1) | ES2471122T3 (https=) |
| MX (1) | MX2010009974A (https=) |
| PL (1) | PL2262506T3 (https=) |
| PT (1) | PT2262506E (https=) |
| RU (1) | RU2481842C2 (https=) |
| SI (1) | SI2262506T1 (https=) |
| TW (1) | TWI468165B (https=) |
| UY (1) | UY31699A1 (https=) |
| WO (1) | WO2009114521A1 (https=) |
| ZA (1) | ZA201005839B (https=) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070202186A1 (en) | 2006-02-22 | 2007-08-30 | Iscience Interventional Corporation | Apparatus and formulations for suprachoroidal drug delivery |
| EP2262506B1 (en) * | 2008-03-11 | 2014-05-07 | Alcon Research, Ltd. | Low viscosity, highly flocculated triamcinolone acetonide suspensions for intravitreal injection |
| AU2009330517A1 (en) * | 2008-12-22 | 2010-07-01 | Alcon Research, Ltd. | Compositions of topical ocular solutions to deliver effective concentrations of active agent to the posterior segment of the eye |
| US20120271272A1 (en) | 2010-10-15 | 2012-10-25 | Iscience Interventional Corporation | Device for ocular access |
| CN102008488B (zh) * | 2010-11-24 | 2012-10-10 | 广州固志医药科技有限公司 | 一种曲安奈德眼用制剂及其制备方法 |
| AR090775A1 (es) * | 2012-04-23 | 2014-12-03 | Otsuka Pharma Co Ltd | Preparado inyectable |
| EP2916827B1 (en) * | 2012-11-08 | 2020-06-10 | Clearside Biomedical Inc. | Methods for the treatment of ocular disease in human subjects |
| SG10201702674PA (en) | 2013-05-03 | 2017-06-29 | Clearside Biomedical Inc | Apparatus and methods for ocular injection |
| EP3003454B1 (en) | 2013-06-03 | 2020-01-08 | Clearside Biomedical, Inc. | Apparatus for drug delivery using multiple reservoirs |
| RU2710491C2 (ru) | 2014-06-20 | 2019-12-26 | Клиасайд Байомедикал, Инк. | Устройство для инъекции лекарственного средства в глазную ткань и способ инъекции лекарственного средства в глазную ткань |
| US9694145B1 (en) | 2016-03-29 | 2017-07-04 | Joseph Onorato | Auto-injector systems and method for delivering cyst medication on demand |
| CA3062845A1 (en) | 2016-05-02 | 2017-11-09 | Clearside Biomedical, Inc. | Systems and methods for ocular drug delivery |
| EP3496680B1 (en) | 2016-08-12 | 2024-10-02 | Clearside Biomedical, Inc. | Device for adjusting the insertion depth of a needle for medicament delivery |
| WO2018204515A1 (en) | 2017-05-02 | 2018-11-08 | Georgia Tech Research Corporation | Targeted drug delivery methods using a microneedle |
| WO2019136512A1 (en) * | 2018-01-10 | 2019-07-18 | Eye Co Pty Ltd | Medical device and pharmaceutical composition for treatment of an eye disease or condition |
| USD893715S1 (en) | 2018-11-06 | 2020-08-18 | Joseph Onorato | Measurement guide for a cyst, lesion or skin disorder |
| WO2020214799A1 (en) * | 2019-04-16 | 2020-10-22 | Clearside Biomedical, Inc. | Injectable triamcinolone formulations |
| US10814001B1 (en) | 2019-05-06 | 2020-10-27 | Rvl Pharmaceuticals, Inc. | Oxymetazoline compositions |
| CN114010593A (zh) * | 2021-11-23 | 2022-02-08 | 莱默(北京)药业科技有限公司 | 一种曲安奈德混悬注射液及制备方法 |
| CN115969784B (zh) * | 2022-12-26 | 2025-10-21 | 昆明积大制药股份有限公司 | 曲安奈德注射液的制备方法 |
| WO2025114562A1 (en) * | 2023-11-30 | 2025-06-05 | Institut National de la Santé et de la Recherche Médicale | Intravitreal spironolactone suspension |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3962430A (en) * | 1974-08-07 | 1976-06-08 | Merck & Co., Inc. | Sterilization of solid non-electrolyte medicinal agents employing sodium chloride |
| US4370325A (en) * | 1979-03-30 | 1983-01-25 | Dermik Laboratories | Pharmaceutical compositions and method of treatment |
| US4432964A (en) * | 1981-08-24 | 1984-02-21 | Alza Corporation | Topical composition containing steroid in two forms released independently from polymeric carrier |
| US5164190A (en) * | 1990-12-11 | 1992-11-17 | Theratech, Inc. | Subsaturated transdermal drug delivery device exhibiting enhanced drug flux |
| WO1995003807A1 (en) | 1993-07-27 | 1995-02-09 | The University Of Sydney | Treatment of age-related macular degeneration |
| WO1996020712A1 (en) | 1994-12-30 | 1996-07-11 | American Home Products Corporation | Clear non-alcoholic hydrocortisone solutions |
| CA2336703A1 (en) | 1998-07-10 | 2000-01-20 | The University Of Sydney | Prophylactic treatments of neovascularisation in macular degeneration |
| AR026073A1 (es) | 1999-10-20 | 2002-12-26 | Nycomed Gmbh | Composicion farmaceutica acuosa que contiene ciclesonida |
| AUPQ496500A0 (en) | 2000-01-06 | 2000-02-03 | University Of Sydney, The | Kit |
| US6395294B1 (en) | 2000-01-13 | 2002-05-28 | Gholam A. Peyman | Method of visualization of the vitreous during vitrectomy |
| US6656505B2 (en) * | 2000-07-21 | 2003-12-02 | Alpharma Uspd Inc. | Method for forming an aqueous flocculated suspension |
| ES2396598T3 (es) * | 2000-08-25 | 2013-02-22 | Senju Pharmaceutical Co., Ltd. | Preparaciones en forma de suspensiones acuosas |
| EP1414466B1 (en) * | 2001-07-09 | 2009-08-19 | CombinatoRx, Incorporated | Combinations for the treatment of inflammatory disorders |
| US20030129242A1 (en) | 2002-01-04 | 2003-07-10 | Bosch H. William | Sterile filtered nanoparticulate formulations of budesonide and beclomethasone having tyloxapol as a surface stabilizer |
| CA2516782A1 (en) | 2003-02-20 | 2004-09-02 | Alcon, Inc. | Use of steroids to treat ocular disorders |
| US20040186084A1 (en) | 2003-03-21 | 2004-09-23 | Akorn, Inc. | Triamcinolone formulations and methods for their preparation and use |
| CA2539023A1 (en) * | 2003-09-23 | 2005-04-14 | Alcon Inc. | Triamcinolone acetonide and anecortave acetate formulations for injection |
| US20050101582A1 (en) | 2003-11-12 | 2005-05-12 | Allergan, Inc. | Compositions and methods for treating a posterior segment of an eye |
| US20070224278A1 (en) | 2003-11-12 | 2007-09-27 | Lyons Robert T | Low immunogenicity corticosteroid compositions |
| US20060141049A1 (en) | 2003-11-12 | 2006-06-29 | Allergan, Inc. | Triamcinolone compositions for intravitreal administration to treat ocular conditions |
| JP2007516297A (ja) * | 2003-12-23 | 2007-06-21 | アルザ・コーポレーシヨン | 制御送達用薬剤組成物の溶解度を高くする方法および投薬形態物 |
| EP1706095B1 (en) | 2004-01-20 | 2008-12-24 | Allergan, Inc. | Compositions for localized therapy of the eye, comprising preferably triamcinolone acetonide and hyaluronic acid |
| US20050244469A1 (en) * | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Extended therapeutic effect ocular implant treatments |
| WO2005115411A1 (ja) | 2004-05-31 | 2005-12-08 | Senju Pharmaceutical Co, .Ltd. | 透明組織可視化剤 |
| US8246949B2 (en) | 2004-10-27 | 2012-08-21 | Aciont, Inc. | Methods and devices for sustained in-vivo release of an active agent |
| EP1827378A2 (en) | 2004-11-17 | 2007-09-05 | Government of The United States of America, as represented by Secretary, Department of Health and Human Services | Steroid formulation and methods of treatment using same |
| EP1867334A4 (en) * | 2005-02-18 | 2009-07-15 | Santen Pharmaceutical Co Ltd | METHOD FOR RELIEVING OR AVOIDING A SECONDARY EFFECT OF A STEROID COMPOUND |
| US7893040B2 (en) * | 2005-07-22 | 2011-02-22 | Oculis Ehf | Cyclodextrin nanotechnology for ophthalmic drug delivery |
| ITRM20050547A1 (it) | 2005-11-04 | 2007-05-05 | Sooft Italia S R L | Gel oftalmico composto da triamcinolone acetonide e da un polimero poliacrilico. |
| EP2262506B1 (en) * | 2008-03-11 | 2014-05-07 | Alcon Research, Ltd. | Low viscosity, highly flocculated triamcinolone acetonide suspensions for intravitreal injection |
-
2009
- 2009-03-10 EP EP09720520.7A patent/EP2262506B1/en active Active
- 2009-03-10 CN CN2009801076823A patent/CN101959519B/zh active Active
- 2009-03-10 RU RU2010141542/15A patent/RU2481842C2/ru active
- 2009-03-10 KR KR1020107022609A patent/KR101555293B1/ko active Active
- 2009-03-10 MX MX2010009974A patent/MX2010009974A/es active IP Right Grant
- 2009-03-10 ES ES09720520.7T patent/ES2471122T3/es active Active
- 2009-03-10 US US12/401,168 patent/US8128960B2/en active Active
- 2009-03-10 SI SI200930950T patent/SI2262506T1/sl unknown
- 2009-03-10 WO PCT/US2009/036652 patent/WO2009114521A1/en not_active Ceased
- 2009-03-10 PT PT97205207T patent/PT2262506E/pt unknown
- 2009-03-10 BR BRPI0909630A patent/BRPI0909630B8/pt active IP Right Grant
- 2009-03-10 DK DK09720520.7T patent/DK2262506T3/da active
- 2009-03-10 PL PL09720520T patent/PL2262506T3/pl unknown
- 2009-03-10 UY UY31699A patent/UY31699A1/es not_active Application Discontinuation
- 2009-03-10 AU AU2009223649A patent/AU2009223649B2/en active Active
- 2009-03-10 CA CA2717605A patent/CA2717605C/en active Active
- 2009-03-10 TW TW98107670A patent/TWI468165B/zh active
- 2009-03-10 JP JP2010550813A patent/JP5581227B2/ja active Active
- 2009-03-11 CL CL2009000573A patent/CL2009000573A1/es unknown
- 2009-03-11 AR ARP090100862A patent/AR070824A1/es unknown
-
2010
- 2010-08-16 ZA ZA2010/05839A patent/ZA201005839B/en unknown
-
2012
- 2012-01-17 US US13/352,009 patent/US8211880B2/en active Active
- 2012-01-17 US US13/352,043 patent/US20120115829A1/en not_active Abandoned